➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Patent: 9,605,043

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,605,043
Title:Fusion protein for suppressing cancer cell growth and suppressing vasculogenesis, and anticancer composition comprising same
Abstract: The present invention relates to a fusion protein resulting from the fusion of a cancer-specific antibody and an angiogenesis inhibitor, and relates to an anti-cancer composition including the same. More specifically, in the present invention, it is preferable that the cancer-specific antibody is trastuzumab or a fragment thereof, and the angiogenesis inhibitor is a VEGF-Trap. When the fusion protein according to the present invention is used, there are advantages in that angiogenesis and cancer cell growth can be effectively inhibited as compared to trastuzumab or VEGF-Trap, and side effects can also be reduced.
Inventor(s): Hong; Hyo Jeong (Seoul, KR), Singh; Rohit (Gangwon-do, KR)
Application Number:14/125,021
Patent Claims:see list of patent claims

Details for Patent 9,605,043

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial GENEONE LIFE SCIENCE, INC. (Seoul, KR) 2031-06-10 RX Orphan search
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial GENEONE LIFE SCIENCE, INC. (Seoul, KR) 2031-06-10 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.